Please use this identifier to cite or link to this item: https://hdl.handle.net/10646/3302
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBall, D.-
dc.date.accessioned2017-06-28T10:17:27Z-
dc.date.available2017-06-28T10:17:27Z-
dc.date.issued2000-
dc.identifier.citationBall, D. (2000). An overview of spontaneous reporting of adverse drug reactions (ARDs) in Zimbabwe. Central African Journal of Medicine, 46 (1), 23-24.en_US
dc.identifier.issn0008-9176-
dc.identifier.urihttp://hdl.handle.net/10646/3302-
dc.description.abstractThe deaths of over 100 people in 1937 in the USA from the ingestion of antifreeze used as a solvent for sulfanilamide and the foetal malformations of thalidomide in Europe in the 1960s resulted in the development of drug regulatory agencies as we know them today.1 These authorities licence medicines for the market using the criteria of safety, efficacy and quality. However, clinical trials are inefficient at determining safety since they involve relatively few, selected patients in controlled prescribing environments. It is necessary to monitor marketed medicines for safety under normal prescribing. This is post marketing surveillance or pharmacovigilance. Various systems are available ranging from compulsory reporting of adverse drug reactions (ADRs) through intensive hospital monitoring to spontaneous voluntary reporting.2 The latter, is more common since it is inexpensive and easy to* * implement whilst being useful in identifying uncommon ADRs.en_US
dc.language.isoen_ZWen_US
dc.publisherUniversity of Zimbabwe, College of Health Sciencesen_US
dc.subjectDrug reactionen_US
dc.titleAn overview of spontaneous reporting of adverse drug reactions (ARDs) in Zimbabween_US
dc.typeArticleen_US
Appears in Collections:Department of Pharmacy Staff Publications

Files in This Item:
File Description SizeFormat 
Ball_An_overview_of_spantaneous_reporting.pdf74.7 kBAdobe PDFThumbnail
View/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.